RCUS Q3 2020 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$65M+3587.4% YoY

Gross Profit

$65M100.0% margin

Operating Income

$2M2.4% margin

Net Income

$2M2.8% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+3587.4%

Cash Flow

Operating Cash Flow

$216M

Free Cash Flow

$215M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$811M

Total Liabilities

$267M

Stockholders' Equity

$544M

Cash & Equivalents

$222M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$65M	$2M	+3587.4%
Gross Profit	$65M	$2M	+3587.4%
Operating Income	$2M	-$23M	+106.7%
Net Income	$2M	-$22M	+108.2%

Revenue Segments

Gilead License To Zimberelimab

$55M85%

Gilead Access Rights

$8M12%

Taiho Collaboration Agreement

$2M3%